Craniometaphyseal Dysplasia: Disease Characteristics Research Report

Executive summary

Craniometaphyseal dysplasia (CMD) is an exceptionally rare, lifelong Mendelian craniotubular bone dysplasia. Its defining combination is progressive craniofacial hyperostosis and flaring/undermodeling of long-bone metaphyses. Morbidity is driven chiefly by narrowing of the skull base and cranial nerve foramina, which can produce hearing loss, facial palsy, visual impairment or blindness, severe headache, and occasionally hindbrain or spinal-cord compression. Autosomal-dominant CMD is caused by heterozygous ANKH variants; a much rarer autosomal-recessive form has been associated with homozygous GJA1 p.Arg239Gln. No approved disease-modifying therapy exists. Management is multidisciplinary surveillance and symptom-directed surgery. The strongest recent therapeutic study, published August 8, 2024, showed that ENPP1-Fc restored plasma pyrophosphate and reduced ectopic calcification in a mouse model but did not correct the core craniofacial or metaphyseal phenotype. (hu2013anovelautosomal pages 1-2, reichenberger2024enpp1enzymereplacement pages 1-2, reichenberger2024enpp1enzymereplacement media 37ae48b6, reichenberger2024enpp1enzymereplacement media 942f6389)

Table: This table condenses the most decision-relevant evidence for craniometaphyseal dysplasia across disease definition, genetics, mechanism, diagnosis, treatment, and models. It is useful as a quick reference for knowledge-base curation while highlighting where evidence remains sparse or preclinical.

1. Disease information

Definition and classification

CMD is a sclerosing skeletal dysplasia/craniotubular dysplasia characterized by abnormal skeletal modeling: progressive thickening and sclerosis of craniofacial bones occur together with broad, flared, relatively undertrabeculated metaphyses of tubular bones. The disorder is genetically and clinically distinct from craniodiaphyseal dysplasia, although older case literature and nonspecific coding can conflate the two. (NCT01630460 chunk 1, hu2013anovelautosomal pages 1-2)

Authoritative abstract wording includes:

“Craniometaphyseal dysplasia (CMD) is a rare genetic bone disorder, characterized by progressive thickening of craniofacial bones and flared metaphyses of long bones.” — Reichenberger et al., advance publication August 8, 2024. (reichenberger2024enpp1enzymereplacement pages 1-2)

Identifiers and synonyms

• MONDO: MONDO:0015465, craniometaphyseal dysplasia. A narrower recessive entity is represented as MONDO:0009035. (OpenTargets Search: craniometaphyseal dysplasia-ANKH,GJA1)
• OMIM/MIM: 123000, classically autosomal-dominant craniometaphyseal dysplasia. (hu2013anovelautosomal pages 1-2)
• Orphanet: CMD is represented in Orphanet as a rare craniotubular bone dysplasia; the exact ORPHA identifier was not verified in the retrieved primary-text evidence and should therefore be validated directly before database ingestion.
• MeSH: No uniquely disease-specific MeSH descriptor was established in the retrieved record. ClinicalTrials.gov maps the record to broader terms including Hyperostosis (D015576); “Schwartz-Lelek syndrome” appears in its automated condition-browse output but should not be treated as the preferred CMD synonym without independent curation. (NCT01630460 chunk 1)
• ICD-10/ICD-11: No specific CMD code was identified. Cases are generally captured under broader osteochondrodysplasia/sclerosing-bone-dysplasia categories; local coding should be checked against the current national modification.
• Common names: craniometaphyseal dysplasia; CMD; autosomal-dominant craniometaphyseal dysplasia; autosomal-recessive craniometaphyseal dysplasia; craniometaphyseal dysplasia, Jackson type is encountered historically.

The evidence summarized here is principally aggregated disease-level literature, supplemented by individual/familial case reports and an observational research protocol. It is not derived from a population EHR cohort.

2. Etiology, risk, protective, and environmental factors

Causal factors

CMD is primarily genetic:

1. Autosomal-dominant CMD: heterozygous pathogenic variants in ANKH, including de novo variants. Human genetic associations were reported in 2001 (PMID 11326338; related ANKH report PMID 11326272). (OpenTargets Search: craniometaphyseal dysplasia-ANKH,GJA1, NCT01630460 chunk 1)
2. Autosomal-recessive CMD: homozygous GJA1 c.716G>A, p.Arg239Gln was identified by exome sequencing and cosegregated with disease in multiple families (PMID 23951358, published August 12, 2013; DOI 10.1371/journal.pone.0073576). (hu2013anovelautosomal pages 2-3, hu2013anovelautosomal pages 1-2)

Risk factors

• The material risk factor is inheritance of a causal germline allele: one pathogenic ANKH allele for dominant CMD, or biallelic pathogenic GJA1 alleles in the reported recessive form.
• Family history raises prior probability, but absence of family history does not exclude CMD because de novo ANKH variants occur. (NCT01630460 chunk 1, hu2013anovelautosomal pages 1-2)
• Consanguinity is relevant to the recessive form: the discovery proband came from a consanguineous family. (hu2013anovelautosomal pages 2-3)
• No reproducible age-, sex-, ethnicity-, toxin-, lifestyle-, occupational-, or infectious-risk factor has been established.

Protective factors and gene–environment interactions

No validated human genetic or environmental protective factor is known. Dietary phosphate restriction improved skeletal abnormalities in an Ank mouse model (PMID 33463757), but this is preclinical and should not be interpreted as a recommended human diet. Conversely, phosphate supplementation did not rescue the mouse phenotype. These observations suggest mineral availability can modify expression in animals, but a clinically actionable human gene–diet interaction is unproven. (reichenberger2024enpp1enzymereplacement pages 9-10, NCT01630460 chunk 1)

There is no established role for smoking, alcohol, exercise, pollution, radiation, toxins, or infectious agents in initiating CMD.

3. Phenotypes

Frequencies are poorly quantified because published evidence consists mainly of small families and case reports. Terms such as “typical,” “frequent,” or “variable” are therefore preferable to unsupported percentages.

The central clinical causal relationship is well summarized in the 2024 paper: craniofacial hyperostosis obstructs neural foramina, producing “facial palsy, blindness, deafness, or severe headache.” Symptoms can progress throughout life. (kanaujiya2018rapiddegradationof pages 1-2, reichenberger2024enpp1enzymereplacement pages 1-2)

In the reported recessive GJA1 case, a three-year-old boy had relative macrocephaly, hypertelorism, a thick bony nasal wedge, depressed/flattened nasal bridge, bilateral nasolacrimal obstruction, skull-base sclerosis, and sclerotic thickening of parietal, occipital, ethmoid, maxillary, and zygomatic bones. Serum calcium, phosphate, and alkaline phosphatase were normal. (hu2013anovelautosomal pages 2-3)

No validated CMD-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life dataset was retrieved. QoL effects must presently be inferred from sensory loss, pain, airway obstruction, facial difference, repeated operations, dental dysfunction, and neurologic disability.

4. Genetic and molecular information

Causal genes

• ANKH — approved name ANKH inorganic pyrophosphate transport regulator; Ensembl ENSG00000154122. It encodes a multipass transmembrane protein involved in small-molecule transport and membrane trafficking. Open Targets identifies ANKH as the highest-scoring CMD-associated target in the retrieved analysis. (OpenTargets Search: craniometaphyseal dysplasia-ANKH,GJA1, reichenberger2024enpp1enzymereplacement pages 1-2)
• GJA1 — gap junction protein alpha 1, encoding connexin-43/Cx43; Ensembl ENSG00000152661, MIM gene 121014. Cx43 is present in osteoblasts, osteocytes, osteoclasts, and chondrocytes and supports intercellular movement of low-molecular-weight molecules. (hu2013anovelautosomal pages 2-3, hu2013anovelautosomal pages 1-2)

Pathogenic variants and consequences

ANKH: CMD variants are predominantly heterozygous, germline, C-terminal cytoplasmic-domain missense substitutions, small in-frame deletions, or insertions. Recurrent examples include p.Phe377del and p.Ser375del. Two large ANKH deletions were reported in sporadic cases (PMID 22150416). The retrieved sources do not supply a complete ClinVar/ACMG inventory, and each variant should be curated at the transcript-specific level before assigning current ACMG classification. (NCT01630460 chunk 1, kanaujiya2018rapiddegradationof pages 1-2, kanaujiya2018rapiddegradationof pages 8-9)

Functional work indicates that p.Phe377del and p.Ser375del proteins have reduced steady-state abundance, accelerated degradation, and abnormal cytoplasmic rather than normal membrane/organelle localization. Coexpression experiments did not show a straightforward dominant-negative effect on wild-type localization or abundance. The most defensible current model is partial loss of normal function plus a possible mutant-specific dominant function, rather than complete loss of function alone. (kanaujiya2018rapiddegradationof pages 1-2, kanaujiya2018rapiddegradationof pages 8-9, reichenberger2024enpp1enzymereplacement pages 4-7)

GJA1: c.716G>A, p.Arg239Gln is a homozygous missense variant in a conserved C-terminal region/potential tubulin-binding motif. At publication it was absent from dbSNP, HGMD, 1000 Genomes, and the NHLBI Exome Sequencing Project. It was found in six affected individuals from three additional families, while parents and unaffected carrier relatives were heterozygous. Its precise bone-remodeling defect remains unresolved. (hu2013anovelautosomal pages 2-3, hu2013anovelautosomal pages 1-2)

Population frequencies should be checked in current gnomAD using exact transcript/genome-build nomenclature. The historic absence data above should not be substituted for a current gnomAD frequency.

Modifiers, epigenetics, and chromosomal abnormalities

• No validated modifier gene explains intrafamilial variability.
• No CMD-specific DNA-methylation, histone, chromatin, transcriptomic, proteomic, metabolomic, lipidomic, spatial-transcriptomic, or single-cell diagnostic signature is established.
• Recessive CMD was historically mapped to 6q21–q22 before GJA1 identification, but CMD is not ordinarily a large chromosomal-abnormality syndrome. (hu2013anovelautosomal pages 1-2)
• Genetic anticipation is not reported.

5. Environmental information

CMD is not an environmentally acquired, infectious, toxic, or lifestyle-mediated disease. No pathogen, vaccine association, occupational exposure, diet, smoking behavior, alcohol exposure, or pollution factor is known to cause it. Environmental management can nevertheless modify complications—for example, hearing/vision accommodation, dental care, airway care, and avoidance of unsupported mineral supplementation—but these are secondary management considerations rather than etiologic factors.

6. Mechanism and pathophysiology

Working causal chain for ANKH-CMD

1. A heterozygous C-terminal ANKH variant alters ANK/ANKH folding, stability, localization, and small-molecule transport.
2. Mutant protein is rapidly degraded through proteasomal and, for endogenous protein, prominently lysosomal pathways; recovered protein remains mislocalized. Wild-type ANK/ANKH normally localizes to plasma membrane, ER, Golgi, lysosomes, and trafficking vesicles. (kanaujiya2018rapiddegradationof pages 1-2, kanaujiya2018rapiddegradationof pages 8-9, reichenberger2024enpp1enzymereplacement pages 1-2)
3. ANK/ANKH-dependent export/release of ATP, pyrophosphate and citrate, together with Golgi–endosomal trafficking, is disturbed. Extracellular ATP can be converted by ENPP1 to AMP plus inorganic pyrophosphate (PPi).
4. PPi normally inhibits hydroxyapatite crystal growth. Reduced local PPi can favor mineral deposition, but restoration of circulating PPi alone does not correct the skeletal phenotype, demonstrating that local, intracellular, remodeling, or mutant-specific mechanisms are also critical. (wathuliyadde2024bonemineralizationregulation pages 1-2, reichenberger2024enpp1enzymereplacement pages 4-7, reichenberger2024enpp1enzymereplacement pages 1-2)
5. Osteoblastogenesis and osteoclastogenesis become dysregulated; patient-derived iPSC work found impaired osteoclast differentiation (PMID 29056330), and the p.Phe377del mouse showed impaired osteoblastogenesis and osteoclastogenesis (PMID 21149338). (NCT01630460 chunk 1)
6. Imbalanced modeling/remodeling causes craniofacial bone accumulation, metaphyseal widening, foraminal stenosis, and downstream cranial-nerve/brainstem complications.

A key cellular-study quote is:

“CMD mutant ANK/ANKH protein is short-lived and mislocalized in cells.” — Kanaujiya et al., Scientific Reports, October 24, 2018, PMID 30356088, DOI 10.1038/s41598-018-34157-5. (kanaujiya2018rapiddegradationof pages 1-2)

GJA1-CMD mechanism

Cx43 gap junctions connect osteoblasts, osteocytes, osteoclasts, and chondrocytes. The p.Arg239Gln variant likely disturbs skeletal-cell communication and coordinated remodeling, but the primary report explicitly states that the affected remodeling mechanism remained to be elucidated. This should be annotated as a credible but incompletely resolved mechanism, not as proven PPi transport dysfunction. (hu2013anovelautosomal pages 1-2)

Ontology suggestions

• GO biological process: bone mineralization (GO:0030282); ossification (GO:0001503); bone remodeling (GO:0046849); osteoblast differentiation (GO:0001649); osteoclast differentiation (GO:0030316); pyrophosphate transport; ATP transport; regulation of biomineral tissue development; endosomal transport; Golgi-to-endosome transport.
• GO cellular component: plasma membrane (GO:0005886); endoplasmic reticulum (GO:0005783); Golgi apparatus (GO:0005794); lysosome (GO:0005764); clathrin-coated vesicle; gap junction (GO:0005921).
• Cell Ontology: osteoblast (CL:0000062); osteoclast (CL:0000092); osteocyte (CL:0000137); chondrocyte (CL:0000138); bone-marrow macrophage/osteoclast precursor.
• CHEBI: inorganic diphosphate/pyrophosphate; ATP; AMP; citrate; hydroxyapatite.

There is no convincing evidence that autoimmunity, immunodeficiency, chronic systemic inflammation, oxidative injury, ischemia, fibrosis, apoptosis, mitochondrial failure, or a primary endocrine defect drives CMD.

7. Anatomical structures affected

Primary sites

• Cranial vault and skull base, including parietal, occipital, frontal, ethmoid, sphenoid/basioccipital regions.
• Facial skeleton: maxilla, zygoma, nasal/paranasal bones, and especially mandible.
• Cranial nerve foramina and foramen magnum; optic canals, internal auditory pathways, and facial-nerve canals are clinically important.
• Metaphyses of femora and other long bones.
• Middle-ear ossicles may be fused in models and hearing pathways can be compromised clinically.
• Teeth and alveolar/jaw bone, with delayed eruption and malocclusion. (wathuliyadde2024bonemineralizationregulation pages 1-2, kanaujiya2018rapiddegradationof pages 1-2, hu2013anovelautosomal pages 2-3)

Secondary structures

Severe skull-base disease can affect cranial nerves, posterior fossa, cervicomedullary junction, spinal cord, paranasal sinuses, nasal airway, and nasolacrimal ducts. Disease is generally bilateral and diffuse rather than characteristically unilateral.

Suggested UBERON annotations include skull (UBERON:0003129), cranial base, mandible (UBERON:0001684), maxilla (UBERON:0001709), femur (UBERON:0000981), long-bone metaphysis, foramen magnum, middle-ear ossicle, optic nerve, facial nerve, and vestibulocochlear nerve.

8. Temporal development

CMD can be recognized in infancy, but onset and severity vary. Craniofacial deposition is chronic and generally progressive throughout life rather than episodic or spontaneously remitting. Facial morphology and metaphyseal changes arise during skeletal development; neurologic and sensory complications can emerge later as foramina narrow. (NCT01630460 chunk 1, reichenberger2024enpp1enzymereplacement pages 1-2)

There is no validated stage system. A practical clinical framework is:

• Early: facial/radiographic findings, metaphyseal flaring, delayed tooth eruption.
• Intermediate: increasing skull-base sclerosis, dental/airway problems, evolving hearing or facial-nerve dysfunction.
• Advanced: optic or other cranial-neuropathy, severe headache/intracranial pressure, foramen-magnum stenosis, Chiari/syrinx or cord compression.

The critical intervention window is before irreversible cranial-nerve injury, although prophylactic operations without objective compromise are not supported by CMD-specific controlled evidence. Recurrence or continued bone growth after contouring/decompression explains why repeated procedures may be necessary.

9. Inheritance and population

• Dominant CMD: autosomal dominant, often familial but sometimes de novo; variable expressivity can occur within a family. (NCT01630460 chunk 1, reichenberger2024enpp1enzymereplacement pages 1-2)
• Recessive CMD: autosomal recessive for the reported GJA1 p.Arg239Gln families; heterozygous relatives were unaffected carriers. (hu2013anovelautosomal pages 2-3)
• Penetrance has not been quantified robustly. No evidence supports anticipation.
• Germline mosaicism is theoretically relevant to apparently de novo cases but was not quantified.
• No confirmed founder effect or population-specific carrier frequency was retrieved.
• Both sexes are affected; no reliable sex ratio or ethnic/geographic enrichment is known.

Epidemiology

No defensible population-based CMD incidence or prevalence estimate was found. It is repeatedly described as “very rare.” The 2024 research article noted that approximately 170 PubMed publications existed, most being clinical reports rather than mechanistic studies; this is a literature-count observation, not a case-count or prevalence estimate. (reichenberger2024enpp1enzymereplacement pages 4-7)

Consequently, incidence per 100,000, point prevalence, carrier frequency, survival rates, and age distribution should be recorded as unknown/not established, rather than inferred from general rare-disease statistics.

10. Diagnostics

Recommended approach

1. Clinical assessment: family history; facial morphology; headache; hearing, facial movement, visual, dental, nasal-airway, sleep, and neurologic symptoms.
2. Radiography: skeletal survey or targeted skull/long-bone radiographs demonstrating craniofacial sclerosis/hyperostosis and metaphyseal flaring/undermodeling.
3. CT: high-resolution assessment of skull-base hyperostosis, foraminal and optic/auditory canal narrowing, sinuses, mandible, and operative anatomy. Minimize cumulative radiation, particularly in children.
4. MRI: brain, posterior fossa, cranial nerves, cervicomedullary junction, Chiari malformation, syringomyelia, or cord compression when indicated.
5. Functional testing: age-appropriate audiology; ophthalmologic examination including acuity, fields and optic-nerve assessment; facial-nerve examination; sleep study when obstruction is suspected; dental/orthodontic evaluation.
6. Laboratory tests: serum calcium, phosphate, alkaline phosphatase, PTH, 25-hydroxyvitamin D, renal function, and urinary mineral studies help assess mimics or coexisting rickets/mineral disorders. Routine values may be normal, as in the reported GJA1 child. There is no validated circulating CMD biomarker. (hu2013anovelautosomal pages 2-3)
7. Molecular confirmation: sequence and copy-number analysis of ANKH first when the phenotype is classic/dominant; include GJA1 for recessive pedigrees or ANKH-negative cases. A broader sclerosing-bone-dysplasia panel or exome/genome sequencing is appropriate when phenotype is atypical or first-line testing is negative. The ClinicalTrials.gov record states that molecular genetics is the best confirmation. (NCT01630460 chunk 1)

WES identified the recessive GJA1 variant at approximately 78× mean depth after linkage and phenotype-guided filtering. WGS may detect noncoding or structural variants in unresolved cases, but CMD-specific incremental diagnostic yield is unknown. CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not routine unless another syndrome is suspected. RNA-seq, proteomics, metabolomics, methylation testing, and liquid biopsy are investigational rather than clinical diagnostics.

Differential diagnosis

Important differentials include craniodiaphyseal dysplasia; osteopetrosis; Camurati–Engelmann disease; frontometaphyseal dysplasia; Pyle disease; osteopathia striata with cranial sclerosis; sclerosteosis/van Buchem disease; hyperphosphatasia with mental retardation syndromes; fluorosis/Paget disease where age appropriate; fibrous dysplasia; TMEM53 craniotubular dysplasia; and oculodentodigital dysplasia. The latter is especially relevant to GJA1, but the reported CMD families lacked the characteristic ocular/dental abnormalities and syndactyly of oculodentodigital dysplasia. (hu2013anovelautosomal pages 1-2)

Screening

CMD is not included in routine newborn screening. Once a familial variant is known, cascade testing, targeted prenatal diagnosis, and preimplantation genetic testing are technically possible following nondirective genetic counseling.

11. Outcome and prognosis

CMD is chronic and lifelong. Life expectancy is not reliably quantified and may be near normal in mildly affected individuals, but severe skull-base disease can cause major morbidity. Principal adverse outcomes are irreversible hearing or vision loss, recurrent facial palsy, chronic headache, dental/airway dysfunction, repeated operations, and uncommon cervicomedullary or spinal-cord compromise. (kanaujiya2018rapiddegradationof pages 1-2, reichenberger2024enpp1enzymereplacement pages 1-2)

No 5-year/10-year survival, disease-specific mortality rate, validated disability scale, prognostic model, or prognostic biomarker exists. Likely clinical prognostic factors are the rate and anatomical distribution of skull-base thickening, severity of foraminal stenosis, early objective nerve dysfunction, and access to multidisciplinary follow-up. A molecular genotype–severity correlation has not been established; the 2018 study explicitly reported no known correlation between individual ANKH variants and clinical expressivity. (kanaujiya2018rapiddegradationof pages 8-9)

Bone removed surgically can regrow as the underlying modeling defect continues. Neurologic recovery depends on whether compression is relieved before permanent nerve injury.

12. Treatment and current implementation

Standard management

No FDA/EMA-approved disease-modifying pharmacotherapy exists. Care should involve clinical genetics, metabolic bone specialists, craniofacial surgery, neurosurgery, otology/audiology, ophthalmology, dentistry/orthodontics, sleep/airway specialists, rehabilitation, and psychosocial support.

• Surgical decompression: for objective, clinically significant optic, auditory/facial nerve, foramen-magnum, or cervicomedullary compression. Suggested NCIt concepts: decompression procedure; craniectomy; foramen-magnum decompression.
• Craniofacial recontouring/reconstruction or orthognathic surgery: for severe deformity, malocclusion, or functional compromise; recurrence can necessitate repeat surgery. Suggested NCIt: reconstructive surgery; osteotomy; maxillofacial surgery.
• Airway procedures: individualized treatment of nasal obstruction or obstructive sleep apnea.
• Hearing/vision support: hearing aids or other auditory rehabilitation where anatomically appropriate; visual aids and disability support.
• Dental care: preventive dentistry, monitoring eruption, orthodontics, and oral/maxillofacial planning.
• Rehabilitation: physical, occupational, speech/hearing, low-vision, pain, and educational support according to deficits.

The contemporary literature states that treatment remains limited to surgical decompression and craniofacial correction, while the 2018 mechanistic paper described “repetitive surgeries to remove hyperostotic bone for symptom relief.” (kanaujiya2018rapiddegradationof pages 1-2, reichenberger2024enpp1enzymereplacement pages 1-2)

Historical pharmacotherapy

Calcitriol and calcitonin have been reported in old, very small case-based literature, with the rationale of modifying bone turnover. The retrieved evidence does not establish durable benefit, standardized dosing, response rates, or safety sufficient for routine disease-modifying use. Bisphosphonates, denosumab, anabolic agents, proteasome/lysosome inhibitors, and systemic phosphate manipulation are likewise not established CMD therapies. Proteolysis inhibitors are specifically unattractive because rescued mutant ANKH remains mislocalized and global inhibition of protein degradation is potentially harmful. (kanaujiya2018rapiddegradationof pages 8-9)

Recent experimental treatment: ENPP1-Fc

Reichenberger et al. treated male and female AnkKI/KI mice with weekly subcutaneous IMA2a from age one week for 12 weeks, with at least six mice per group. ENPP1 activity rose from 28.15 ± 1.65 to 482.7 ± 331.2 mOD/min; plasma PPi was 0.94 ± 0.5 μM in wild type, 0.43 ± 0.2 μM in mutant vehicle controls, and 1.29 ± 0.8 μM in treated mutants (p<0.01). Calcified-nodule volume fell, but skull hyperostosis, mandibular bone mass, metaphyseal widening, abnormal femoral shape, and narrowed foramen magnum did not significantly improve. (reichenberger2024enpp1enzymereplacement pages 4-7, reichenberger2024enpp1enzymereplacement pages 1-2)

The radiographic and μCT figures directly show persistent increased skull radiopacity, mandibular enlargement, metaphyseal flaring, and foramen-magnum narrowing after treatment. (reichenberger2024enpp1enzymereplacement media 37ae48b6, reichenberger2024enpp1enzymereplacement media 942f6389)

This is strong negative translational evidence against the idea that simply normalizing circulating PPi will reverse core CMD. It does not exclude benefit from earlier, local, higher-exposure, combination, gene-directed, or remodeling-directed approaches.

Clinical studies

NCT01630460, “Genetic and Functional Analysis of Craniometaphyseal Dysplasia,” is a prospective observational case-control study at UConn Health, not a treatment trial. It collects saliva, blood, and bone tissue and aims to identify genetic elements affecting cause, progression, and severity. The current record lists estimated enrollment of 600, ages child through older adult, and recruiting status, with completion projected for 2030. URL: ClinicalTrials.gov NCT01630460. (NCT01630460 chunk 1)

No CMD-specific gene therapy, CRISPR therapy, RNA therapy, cell therapy, or controlled drug trial was identified. Pharmacogenomic guidance is not applicable at present.

13. Prevention

Primary prevention

There is no vaccine, lifestyle intervention, environmental avoidance measure, or prophylactic drug that prevents a new germline CMD case. Reproductive options after molecular diagnosis include genetic counseling, partner testing for recessive disease where appropriate, prenatal diagnosis, and preimplantation genetic testing.

For counseling:

• An affected heterozygous ANKH carrier generally has a 50% transmission probability per pregnancy, subject to variant interpretation and parental mosaicism.
• Two carriers of a pathogenic recessive GJA1 allele have the standard 25% affected, 50% carrier, and 25% unaffected/noncarrier probabilities per pregnancy.

Secondary and tertiary prevention

Early molecular diagnosis and cascade testing permit surveillance before irreversible nerve damage. Periodic hearing, vision, neurologic, dental, airway/sleep, and imaging assessment should be individualized. Prompt treatment of objective compression, dental infection, sleep-disordered breathing, and functional deficits constitutes tertiary prevention. Population screening and newborn biochemical screening are not justified by current evidence.

14. Other species and natural disease

No well-established naturally occurring veterinary CMD homolog was identified in the retrieved literature. Accordingly, breed-specific prevalence, VBO terms, zoonotic potential, and cross-species transmission are not applicable/unknown. CMD is genetic and noncommunicable.

Orthologous Ank/ankh genes are evolutionarily conserved across vertebrates. Relevant taxa include:

• Homo sapiens — NCBI Taxonomy 9606
• Mus musculus — 10090
• Danio rerio — 7955

Comparative pathology supports conserved control of mineralization, but species differences are important: joint stiffness in mice is not a typical reported human feature, and heterozygous mice are often milder than human heterozygotes. (wathuliyadde2024bonemineralizationregulation pages 1-2)

15. Model organisms and experimental systems

Mouse models

1. Ank p.Phe377del knock-in (AnkKI/KI): reproduces thick skull, narrowed foramen magnum, fused middle-ear bones, obliterated nasal sinuses, stenotic cranial foramina, mandibular hyperostosis, and widened femoral metaphyses. Landmark reports: PMID 19257826 and PMID 21149338. Dental abnormalities were examined in PMID 23160629. (NCT01630460 chunk 1, wathuliyadde2024bonemineralizationregulation pages 1-2)
2. Ank knockout/null: reproduces partial CMD-like features—thick skull, narrow foramen magnum, fused ossicles—but not the full mandibular, sinus, and metaphyseal phenotype. This supports a loss-of-function component but also indicates a mutant-specific mechanism. (wathuliyadde2024bonemineralizationregulation pages 1-2, reichenberger2024enpp1enzymereplacement pages 4-7)
3. Limitations: severe human-like disease is best reproduced in homozygous knock-in mice even though human ANKH-CMD is heterozygous dominant; mice also develop joint stiffness not typical of human CMD. (wathuliyadde2024bonemineralizationregulation pages 1-2)

Human cellular models

Human induced pluripotent stem-cell differentiation demonstrated that CMD-associated ANKH mutations impair osteoclast differentiation (PMID 29056330). Other studies used patient-derived dental stem cells, osteoclast cultures, mouse embryonic fibroblasts, and transfected cells to study protein abundance, degradation, localization, and bone-cell differentiation. These are useful for target validation but do not reproduce whole-organ skull biomechanics. (NCT01630460 chunk 1, kanaujiya2018rapiddegradationof pages 1-2)

Zebrafish

A March 26, 2024 bioRxiv study identified two paralogs, ankha and ankhb. Both were expressed in craniofacial regions, notochord, and somites; ankha was relatively prominent earlier and ankhb during larval growth. The authors proposed CRISPR models and high-throughput therapeutic screening, but exact paralog functions remain speculative. DOI 10.1101/2024.03.21.586098. This work was a preprint in the retrieved version and should not be weighted like peer-reviewed interventional evidence. (wathuliyadde2024bonemineralizationregulation pages 7-9, wathuliyadde2024bonemineralizationregulation pages 1-2)

Recent developments and expert interpretation, 2023–2024

1. 2024 ENPP1-Fc study: normalization of circulating PPi was biologically active but insufficient to rescue skeletal modeling. Expert interpretation: systemic PPi deficiency is probably not the sole or dominant upstream driver; intracellular ANK function, local bone PPi, citrate/ATP transport, remodeling-cell coupling, and mutant-specific effects deserve priority. (reichenberger2024enpp1enzymereplacement pages 4-7, reichenberger2024enpp1enzymereplacement pages 1-2)
2. 2024 zebrafish work: established developmental-expression groundwork for scalable functional analysis, but not yet a validated disease model or therapy platform. (wathuliyadde2024bonemineralizationregulation pages 1-2)
3. Ongoing natural-history/genetics effort: NCT01630460 remains the principal registered CMD-specific study identified, emphasizing that the field still lacks robust cohorts and molecular predictors. (NCT01630460 chunk 1)
4. Research gap: recent CMD literature remains sparse. Most evidence is case-based or preclinical; phenotype frequencies, incidence, validated patient-reported outcomes, genotype–phenotype prediction, and controlled treatment outcomes are not available.

Knowledge-base curation cautions

• Keep ANKH-autosomal dominant CMD and GJA1-autosomal recessive CMD as related but genetically distinct entities.
• Do not encode reduced plasma PPi as a universal validated human biomarker; the strongest quantitative data are from mice.
• Do not infer prevalence or phenotype percentages from case-report counts.
• Do not classify all ANKH variants as simple null alleles: current evidence supports reduced function plus possible mutant-specific effects.
• Mark calcitriol, calcitonin, dietary phosphate restriction, and ENPP1-Fc as historical or experimental—not standard disease-modifying care.
• Record absent omics, epigenetic, epidemiologic, survival, and QoL information explicitly as not established, rather than negative biological findings.

References

1. (hu2013anovelautosomal pages 1-2): Ying Hu, I-Ping Chen, Salome de Almeida, Valdenize Tiziani, Cassio M. Raposo Do Amaral, Kalpana Gowrishankar, Maria Rita Passos-Bueno, and Ernst J. Reichenberger. A novel autosomal recessive gja1 missense mutation linked to craniometaphyseal dysplasia. PLoS ONE, 8:e73576, Aug 2013. URL: https://doi.org/10.1371/journal.pone.0073576, doi:10.1371/journal.pone.0073576. This article has 84 citations and is from a peer-reviewed journal.

2. (reichenberger2024enpp1enzymereplacement pages 1-2): Ernst J. Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, and I-Ping Chen. Enpp1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR Plus, Aug 2024. URL: https://doi.org/10.1093/jbmrpl/ziae103, doi:10.1093/jbmrpl/ziae103. This article has 5 citations and is from a peer-reviewed journal.

3. (reichenberger2024enpp1enzymereplacement media 37ae48b6): Ernst J. Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, and I-Ping Chen. Enpp1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR Plus, Aug 2024. URL: https://doi.org/10.1093/jbmrpl/ziae103, doi:10.1093/jbmrpl/ziae103. This article has 5 citations and is from a peer-reviewed journal.

4. (reichenberger2024enpp1enzymereplacement media 942f6389): Ernst J. Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, and I-Ping Chen. Enpp1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR Plus, Aug 2024. URL: https://doi.org/10.1093/jbmrpl/ziae103, doi:10.1093/jbmrpl/ziae103. This article has 5 citations and is from a peer-reviewed journal.

5. (NCT01630460 chunk 1): Ernst Reichenberger. Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD). UConn Health. 2009. ClinicalTrials.gov Identifier: NCT01630460

6. (wathuliyadde2024bonemineralizationregulation pages 1-2): Nuwanthika Wathuliyadde, Katherine E. Willmore, and Gregory M. Kelly. Bone mineralization regulation: using zebrafish as a model to study ankh-associated mineralization disorders. bioRxiv, Mar 2024. URL: https://doi.org/10.1101/2024.03.21.586098, doi:10.1101/2024.03.21.586098. This article has 1 citations.

7. (kanaujiya2018rapiddegradationof pages 1-2): Jitendra Kanaujiya, Edward Bastow, Raj Luxmi, Zhifang Hao, Dimitrios Zattas, Mark Hochstrasser, Ernst J. Reichenberger, and I-Ping Chen. Rapid degradation of progressive ankylosis protein (ankh) in craniometaphyseal dysplasia. Scientific Reports, Oct 2018. URL: https://doi.org/10.1038/s41598-018-34157-5, doi:10.1038/s41598-018-34157-5. This article has 20 citations and is from a peer-reviewed journal.

8. (kanaujiya2018rapiddegradationof pages 8-9): Jitendra Kanaujiya, Edward Bastow, Raj Luxmi, Zhifang Hao, Dimitrios Zattas, Mark Hochstrasser, Ernst J. Reichenberger, and I-Ping Chen. Rapid degradation of progressive ankylosis protein (ankh) in craniometaphyseal dysplasia. Scientific Reports, Oct 2018. URL: https://doi.org/10.1038/s41598-018-34157-5, doi:10.1038/s41598-018-34157-5. This article has 20 citations and is from a peer-reviewed journal.

9. (OpenTargets Search: craniometaphyseal dysplasia-ANKH,GJA1): Open Targets Query (craniometaphyseal dysplasia-ANKH,GJA1, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

10. (hu2013anovelautosomal pages 2-3): Ying Hu, I-Ping Chen, Salome de Almeida, Valdenize Tiziani, Cassio M. Raposo Do Amaral, Kalpana Gowrishankar, Maria Rita Passos-Bueno, and Ernst J. Reichenberger. A novel autosomal recessive gja1 missense mutation linked to craniometaphyseal dysplasia. PLoS ONE, 8:e73576, Aug 2013. URL: https://doi.org/10.1371/journal.pone.0073576, doi:10.1371/journal.pone.0073576. This article has 84 citations and is from a peer-reviewed journal.

11. (reichenberger2024enpp1enzymereplacement pages 4-7): Ernst J. Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, and I-Ping Chen. Enpp1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR Plus, Aug 2024. URL: https://doi.org/10.1093/jbmrpl/ziae103, doi:10.1093/jbmrpl/ziae103. This article has 5 citations and is from a peer-reviewed journal.

12. (reichenberger2024enpp1enzymereplacement pages 9-10): Ernst J. Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, and I-Ping Chen. Enpp1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR Plus, Aug 2024. URL: https://doi.org/10.1093/jbmrpl/ziae103, doi:10.1093/jbmrpl/ziae103. This article has 5 citations and is from a peer-reviewed journal.

13. (wathuliyadde2024bonemineralizationregulation pages 7-9): Nuwanthika Wathuliyadde, Katherine E. Willmore, and Gregory M. Kelly. Bone mineralization regulation: using zebrafish as a model to study ankh-associated mineralization disorders. bioRxiv, Mar 2024. URL: https://doi.org/10.1101/2024.03.21.586098, doi:10.1101/2024.03.21.586098. This article has 1 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.